Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

Neuralgia,Postherpetic Clinical Trial

Official title:

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00636636
• Other study ID #: 81-0062
• Status: Completed
• Phase: Phase 3
• First received: February 21, 2008
• Last updated: February 21, 2012
• Start date: March 2008
• Est. completion date: September 2009

Study information

• Verified date: February 2012
• Source: Depomed
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control. The purpose of this study is to determine whether a new gabapentin tablet, which only needs to be taken once a day, is safe and effective for the treatment of postherpetic neuralgia.

Description:

The primary study objective is to assess the relative efficacy of G-ER dosed once daily (1800 mg following the evening meal), versus placebo in reducing the mean daily pain score from the baseline week to the end of the efficacy treatment period (Treatment Week 10) in patients with PHN.

Secondary efficacy measures will include changes from baseline in mean weekly sleep interference scores, Short-Form McGill Pain Questionnaire (SF-MPQ), the Neuropathic Pain Scale (NPS), Brief Pain Inventory (BPI), Patient Global Impression of Change (PGIC), and Investigator-Rated Clinical Global Impression of Change (CGIC).

Other known NCT identifiers

• NCT01465321

Recruitment information / eligibility

• Status: Completed
• Enrollment: 452
• Est. completion date: September 2009
• Est. primary completion date: August 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Men or women 18 years or older who have experienced pain for at least 6 months, but not more than 5 years after the healing of a herpes zoster skin rash(typically about 4 months after the rash first appears).

2. Patient has a pain intensity score of at least 4 on the 11-point Numerical Rating Scale (NRS). Patients should never be informed of the pain intensity criterion prior to screening or randomization.

3. Patients of child-bearing potential must have a negative serum pregnancy test at screening and a negative follow-up urine pregnancy test at randomization.

4. Patient has a mean baseline week pain intensity score of at least 4 on the 11-point NRS scale at the end of a 1-week baseline period and has completed at least 4 days of daily pain diary entries during the baseline week.

5. Patients must have a minimum washout period of greater than 5 times the half-life of the drug of several medications.

6. Patients currently treated with gabapentin pr pregabalin at screening may be eligible for the study, but must have a tapering period wherein the dose of gabapentin or pregabalin is reduced gradually over a period of 5 days followed by a two day washout prior to the Baseline Week.

Exclusion Criteria:

1. Patients who have previously not responded to treatment for PHN with gabapentin or pregabalin.

2. Patients who previously experienced dose-limiting adverse effects that prevented titration of gabapentin to an effective dose.

3. Patient is a nursing mother.

4. Patient has hypersensitivity to gabapentin.

5. Patient has had neurolytic or neurosurgical treatment for PHN.

6. Patient has severe pain from causes other than PHN.

7. Patient has used injected anesthetics or steroids within 30 days of baseline.

8. Patient has skin conditions in the area affected by the neuropathy that could alter sensation.

9. Patient is in an immunocompromised state.

10. Patient has an estimated creatinine clearance less than 50 ml/min.

11. Patient has had malignancy within past 2 years other than basal cell carcinoma.

12. Patient has had gastric reduction surgery.

13. Patient has severe chronic diarrhea, chronic constipation [unless attributed to drugs that will be washed out], uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss.

14. Patient has any abnormal chemistry or hematology results that are deemed by the investigator to be clinically significant.

15. Patient has a history of substance abuse within the past year.

16. Patient has a history of seizure (except for infantile febrile seizure) or is at risk of seizure due to head trauma.

17. Patient has a history of chronic hepatitis B or C, hepatitis within the past 3 months, or HIV infection.

18. Patient has any other clinically significant medical or psychological condition that, in the opinion of the Investigator would jeopardize the safety of the patient or affect the validity of the study results.

19. Continuing use of any concomitant medication excluded by Inclusion Criterion 5.

20. Patient has participated in a clinical trial of an investigational drug or device within 30 days of the screening visit.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neuralgia
• Neuralgia, Postherpetic
• Neuralgia,Postherpetic

Intervention

Drug:
• Gabapentin Extended Release tablets
Once-Daily; 300 mg and 600 mg tablets
• Placebo
Once daily; 300 mg and 600 mg tablets

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Depomed

Countries where clinical trial is conducted

United States,  Argentina,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score	Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily pain score from baseline to the final week of efficacy treatment period (Week 10).	10 weeks	No
Secondary	Patient Global Impression of Change (PGIC)	Patient self-assessment of how much pain had changed at end of treatment period (Week 10) compared to pain at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).	10 weeks	No
Secondary	Clinical Global Impression of Change (CGIC)	Investigator assessment of patient's overall PHN symptoms at end of treatment period (Week 10) compared to overall PHN symptoms at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).	10 weeks	No
Secondary	Average Daily Sleep Interference Score	Assessed on 11-point numeric rating scale (where 0 = pain does not interfere with sleep, 10 = pain completely interferes with sleep); evaluated from daily sleep entry in electronic diary. Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily sleep interference score from baseline to final week of treatment period (Week 10).	10 weeks	No